Highly Galactosylated Anti-IL23 (Tildrakizumab) Antibody (CAT#: BioBet-GA-014ZP) Datasheet

IL23A

interleukin 23 subunit alpha

This gene encodes a subunit of the heterodimeric cytokine interleukin 23 (IL23). IL23 is composed of this protein and the p40 subunit of interleukin 12 (IL12B). The receptor of IL23 is formed by the beta 1 subunit of IL12 (IL12RB1) and an IL23 specific subunit, IL23R. Both IL23 and IL12 can activate the transcription activator STAT4, and stimulate the production of interferon-gamma (IFNG). In contrast to IL12, which acts mainly on naive CD4(+) T cells, IL23 preferentially acts on memory CD4(+) T cells.

P19; SGRF; IL-23; IL-23A; IL23P19

Extracellular region or secreted

Its related pathways are Tuberculosis and PEDF Induced Signaling.

Combined with IL12B to form IL-23 interleukin, which is a heterodimeric cytokine that plays a role in innate immunity and adaptive immunity. IL-23 and IL-17 may constitute an acute response to surrounding tissue infection. IL-23 binds to the heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory instead of naive T cells, and promotes the production of pro-inflammatory cytokines. IL-23 induces autoimmune inflammation, so it may be the cause of autoimmune inflammatory diseases and may be important for tumor occurrence.

No Post-translational modifications

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Tildrakizumab

Mouse

Human

Tildrakizumab is a humanized IgG1κ antibody designed to treat monoclonal antibodies against immune-mediated inflammatory diseases.

Moderate-severe plaque psoriasis

tildrakizumab-asmn

IL-23 is a naturally occurring cytokine involved in inflammation and immune responses. Studies have shown that targeting IL-23p19 alone is a promising method for treating patients with moderate to severe chronic plaque psoriasis.
Tildrakizumab is a humanized IgG1κ antibody used to block interleukin-23. The drug selectively binds to the IL-23 p19 subunit and neutralizes its function. IL-23 regulates Th17 cells and is a potent activator of keratinocyte proliferation. Tildrakizumab inhibits the release of pro-inflammatory cytokines and chemokine tags.
As tildrakizumab is an IgG1 antibody, it has the potential to induce ADCC and / or CDC.

Moderate-severe plaque psoriasis